Skip to Main Content
Beta test
our new site.
(
NLM Technical Bulletin
)
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Randomized Study of Albendazole in Patients With Epilepsy Due to Neurocysticercosis
The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2001
by FDA Office of Orphan Products Development.
Recruitment status was Active, not recruiting
Study NCT00004403 Information provided by FDA Office of Orphan Products Development
First Received on October 18, 1999. Last Updated on June 23, 2005
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Epilepsy
Cysticercosis
Additional conditions recognized in this trial
Neurocysticercosis
Taeniasis
More general conditions related to this trial
Brain Diseases
Central Nervous System Diseases
Central Nervous System Helminthiasis
Central Nervous System Infections
Central Nervous System Parasitic Infections
Cestode Infections
Helminthiasis
Nervous System Diseases
Parasitic Diseases
Interventions listed in this trial
albendazole
dexamethasone
phenytoin
Additional drug interventions recognized in this trial
BB 1101
Dexamethasone 21-phosphate
Dexamethasone acetate
More general drug interventions related to this trial
Anthelmintics
Anti-Infective Agents
Anti-Inflammatory Agents
Anticestodal Agents
Anticonvulsants
Antiemetics
Antimitotic Agents
Antineoplastic Agents
Antineoplastic Agents, Hormonal
Antiparasitic Agents
Antiplatyhelmintic Agents
Antiprotozoal Agents
Autonomic Agents
Central Nervous System Agents
Enzyme Inhibitors
Gastrointestinal Agents
Glucocorticoids
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Therapeutic Uses
Tubulin Modulators
Sponsors listed in this trial
FDA Office of Orphan Products Development
Johns Hopkins University
Back to top of Main Content
